RDYDr. Reddy's Laboratories Limited
Is it growing?
Neither accelerating nor breaking down: operating margin widening (+1.3 points), but earnings down −24% year on year.
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +12% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.
Trailing-twelve-month operating margin, 15.0% now against 13.7% a year earlier.
All from SEC EDGAR, as of Mar 31, 2026.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is RDY growing?
Dr. Reddy's Laboratories Limited's revenue has grown 11% a year over three years, and grown 12% a year over five, with earnings per share falling 1.7% a year.
Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +12% · steady growth, ahead of inflation · compounded from fiscal years as filed
- Revenue growth, 5-year rate
- +12%
Revenue growth, 5-year rate · +11% over three · growth has slowed since the five-year average
- Earnings per share, 3-year rate
- −1.7%
Earnings per share, 3-year rate · revenue +11% · earnings lagged revenue: the growth is costing something
- Years of annual history on file
- 11
Years of annual history on file · FY2016 to FY2026, as filed
Details›
- Revenue FY2022
- $214.4B
- Revenue FY2023
- $245.9B
- Revenue FY2024
- $279.2B
- Revenue FY2025
- $325.5B
- Revenue FY2026
- $335.9B
Annual income statements as filed with the SEC.
Drug Manufacturers, Specialty & Generic
Ranks #2 of 39 by RyuScore